Snapshot from Sep 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial failure

Novartis pelacarsen trial fails endpoint

Analysis based on 12 articles · First reported Sep 04, 2026 · Last updated Sep 05, 2026

Sentiment
-20
Attention
4
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The failed trial removes a potential future revenue stream for Royalty Pharma and Ionis, but Royalty Pharma's protective structure limits downside. Novartis faces a setback in its cardiovascular pipeline, while Ionis loses expected milestone payments.

Biopharmaceutical Healthcare

Royalty Pharma announced that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide for patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a), did not meet its primary endpoint of reducing cardiovascular events compared to placebo. Novartis plans to present the data at an upcoming medical congress. Royalty Pharma's $500 million funding agreement with Ionis was structured protectively, with $150 million allocated to pelacarsen royalties and $350 million to Spinraza royalties. Royalty Pharma expects to recoup its investment and earn a modest positive return, reiterates its 2030 Portfolio Receipts target of $4.7 billion or more, and does not anticipate making milestone payments to Ionis. Its Spinraza royalty interest will revert to Ionis after royalty payments reach $550 million, representing a 1.1x return.

95 Novartis reported failed trial
80 Royalty Pharma announced trial failure
70 Royalty Pharma expects recoup investment
60 Royalty Pharma will not pay milestones Ionis Pharmaceuticals
50 Royalty Pharma reiterated receipts target
stock
Royalty Pharma announced the trial failure and expects to recoup its investment due to protective structuring, reiterating its 2030 target.
Importance 100.0 Sentiment 0.0
stock
Novartis' pelacarsen trial failed its primary endpoint, a setback for its cardiovascular pipeline.
Importance 90.0 Sentiment -30.0
stock
Ionis will not receive milestone payments from Royalty Pharma and loses potential pelacarsen royalties, though Spinraza royalties continue.
Importance 80.0 Sentiment -40.0
stock
Biogen is mentioned as a partner in Spinraza royalties, but the trial failure has no direct impact on its existing products.
Importance 20.0 Sentiment 0.0
stock
Vertex is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
stock
GSK is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
stock
Roche is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
stock
Johnson & Johnson is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
priv
Laboratoires Servier is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
stock
AbbVie is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
stock
Astellas is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
stock
Pfizer is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
stock
Gilead is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Importance 5.0 Sentiment 0.0
Novartis related ↔ Roche
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.